SABCS 2020 | SWOG S9313: classification of TNBC by DNA damage response + homologous recombination deficiency

Shane Stecklein, MD, PhD, University of Kansas Medical Center, Kansas City, KS, updates us on the SWGO S9313 adjuvant, Phase III study comparing adjuvant chemotherapy with high-dose cyclophosphamide plus doxorubicin versus sequential doxorubicin followed by cyclophosphamide in high-risk breast cancer patients with 0 – 3 positive nodes. Dr Stecklein highlights the classification of triple-negative breast cancer (TNBC) by DNA damage immune response signature and homologous recombination deficiency status, which was found to be a prognostic factor in the outcomes of patients with TNBC. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).